SARS-Cov-2 Infection and Pulmonary Thromboembolism - The Prothrombotic State in COVID-19

Introduction The COVID-19 caused by new coronavirus, named by the World Health Organization as Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), has spread all over the world with astonishing speed.(1) In Brazil, the spread risk (RO) of COVID-19 has been 3.0, which explains its rapid dissemination all over the states.(2) Individuals with cardiovascular diseases, systemic arterial hypertension, diabetes mellitus, chronic obstructive pulmonary disease, and immunosuppressed patients are at higher risk for adverse outcomes.(3) A relatively high incidence of thrombotic and thromboembolic disease has been observed in COVID-19 carriers, probably due to direct effects of the SARS-CoV-2 or indirect mechanisms of the infection. Interactions between COVID-19 therapies and anti platelet agents or anticoagulants and the inadvertent use of anticoagulants may contribute to the prothrombotic state of the disease.(4) Objectives Here we describe a patient diagnosed with SARS-CoV-2 progressing with pulmonary thrornboernbolism and no evidence off peripheral thrombosis. Methods The data here reported were obtained by review of electronic medical records, complementary tests, and literature review.